A PHASE 2/3, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY

Registry ID

417-201-00012

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION INC

Start date

2024-06-15

Last update

2022-06-16

Conditions

• IMMUNOGLOBULIN A NEPHROPATHY

Related clinical trials

• A PHASE 2B, MULTICENTER, OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE IMPACT OF SIBEPRENLIMAB ON KIDNEY HISTOPATHOLOGY THROUGH REPEAT KIDNEY BIOPSIES IN ADOLESCENTS AND ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY (RAINIER)
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIS649 IN PARTICIPANTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY.
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF OMS721 IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY (ARTEMIS-IGAN)

View on source registry